Table 1.
Physicochemical characteristics of different liposomal formulations.
| Liposomal Formulation | [PTX] (mg/mL) | [DXR] (mg/mL) | PTX/DXR Molar Ratio | Mean Diameter (nm) | PDI | Zeta Potential (mV) |
|---|---|---|---|---|---|---|
| LCFP-Blank | - | - | - | 228.5 ± 10.14 | 0.33 ± 0.06 | −5.25 ± 0.67 |
| LCFP-PTX | 0.12 ± 0.01 | - | - | 247.0 ± 4.3 | 0.31 ± 0.04 | −5.07 ± 0.65 |
| LCFP-DXR | - | 1.72 ± 0.39 | - | 226.4± 26.9 | 0.27± 0.03 | −4.42 ± 1.38 |
| LCFP-PTX/DXR (10:1) | 0.13 ± 0.02 | 0.01 ± 0.00 | 9.82 ±0.24 | 249.8 ± 12.3 | 0.29 ± 0.01 | −6.86 ± 1.67 |
| LCFP-PTX/DXR (1:1) | 0.12 ± 0.02 | 0.08 ± 0.01 | 0.98 ± 0.07 | 236.3 ± 5.1 | 0.29 ± 0.02 | −6.40 ± 1.78 |
| LCFP-PTX/DXR (1:10) | 0.14 ± 0.03 | 0.81 ± 0.14 | 0.11 ± 0.05 | 237.1 ± 48.3 | 0.29 ± 0.04 | −4.40 ± 1.31 |
Ratio in parenthesis refers to PTX:DXR molar ratio. Abbreviations: DXR, doxorubicin; PTX, paclitaxel; LCFL, long-circulating and fusogenic liposomes; LCFL-PTX/DXR, long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin; PI, polydispersity index.